ZYBAN, The smoking cessation drug marked for its adverse reactions
GlaxoSmithKline's smoking cessation drug
Zyban, which is being taken by over 5 million people world wide, is held responsilble for a raise in the suspected adverse reactions due to drug intake in UK. Pharmacovigilance statistics of MCA has shown a raise of about 37% more adverse reactions so called "yellow cards" during the period of January to April 2001 compared to that of last years....
Cloud of smoke over Zyban
Can an anti-smoking drug be injurious to health? Pharma giant GlaxoSmithKline (GSK), under fire regarding its smoking cessation drug,
Zyban, has risen in defence of its non-nicotine oral drug - in the wake of unproven reports in the UK, linking the drug to adverse reactions and deaths. // Touted to be the world’s most successful smoking cessation drug,
Zyban received a high decibel l...
Zyban
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories